174 related articles for article (PubMed ID: 24008424)
1. Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.
Prickett TD; Zerlanko B; Gartner JJ; Parker SCJ; Dutton-Regester K; Lin JC; Teer JK; Wei X; Jiang J; Nisc Comparative Sequencing Program ; Chen G; Davies MA; Gershenwald JE; Robinson W; Robinson S; Hayward NK; Rosenberg SA; Margulies EH; Samuels Y
J Invest Dermatol; 2014 Feb; 134(2):452-460. PubMed ID: 24008424
[TBL] [Abstract][Full Text] [Related]
2. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Stark MS; Woods SL; Gartside MG; Bonazzi VF; Dutton-Regester K; Aoude LG; Chow D; Sereduk C; Niemi NM; Tang N; Ellis JJ; Reid J; Zismann V; Tyagi S; Muzny D; Newsham I; Wu Y; Palmer JM; Pollak T; Youngkin D; Brooks BR; Lanagan C; Schmidt CW; Kobe B; MacKeigan JP; Yin H; Brown KM; Gibbs R; Trent J; Hayward NK
Nat Genet; 2011 Dec; 44(2):165-9. PubMed ID: 22197930
[TBL] [Abstract][Full Text] [Related]
3. Thioredoxin Activates MKK4-NFκB Pathway in a Redox-dependent Manner to Control Manganese Superoxide Dismutase Gene Expression in Endothelial Cells.
Kundumani-Sridharan V; Subramani J; Das KC
J Biol Chem; 2015 Jul; 290(28):17505-19. PubMed ID: 26028649
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
5. Structural aspects of protein kinase ASK1 regulation.
Obsil T; Obsilova V
Adv Biol Regul; 2017 Dec; 66():31-36. PubMed ID: 29066278
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis signal-regulating kinase 1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis.
Pramanik KC; Srivastava SK
Antioxid Redox Signal; 2012 Nov; 17(10):1417-32. PubMed ID: 22530568
[TBL] [Abstract][Full Text] [Related]
7. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.
Prickett TD; Zerlanko BJ; Hill VK; Gartner JJ; Qutob N; Jiang J; Simaan M; Wunderlich J; Gutkind JS; Rosenberg SA; Samuels Y
J Invest Dermatol; 2014 Sep; 134(9):2390-2398. PubMed ID: 24739903
[TBL] [Abstract][Full Text] [Related]
9. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
10. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
11. Melanoma mutagenesis and aberrant cell signaling.
Bello DM; Ariyan CE; Carvajal RD
Cancer Control; 2013 Oct; 20(4):261-81. PubMed ID: 24077403
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in signaling pathways in melanoma.
Haluska FG; Tsao H; Wu H; Haluska FS; Lazar A; Goel V
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2301s-2307s. PubMed ID: 16609049
[TBL] [Abstract][Full Text] [Related]
13. Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis.
Niso-Santano M; González-Polo RA; Bravo-San Pedro JM; Gómez-Sánchez R; Lastres-Becker I; Ortiz-Ortiz MA; Soler G; Morán JM; Cuadrado A; Fuentes JM;
Free Radic Biol Med; 2010 May; 48(10):1370-81. PubMed ID: 20202476
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
15. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev SI; Rimoldi D; Iseli C; Valsesia A; Robyr D; Gehrig C; Harshman K; Guipponi M; Bukach O; Zoete V; Michielin O; Muehlethaler K; Speiser D; Beckmann JS; Xenarios I; Halazonetis TD; Jongeneel CV; Stevenson BJ; Antonarakis SE
Nat Genet; 2011 Dec; 44(2):133-9. PubMed ID: 22197931
[TBL] [Abstract][Full Text] [Related]
16. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
17. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
[TBL] [Abstract][Full Text] [Related]
18. Cysteine residues mediate high-affinity binding of thioredoxin to ASK1.
Kylarova S; Kosek D; Petrvalska O; Psenakova K; Man P; Vecer J; Herman P; Obsilova V; Obsil T
FEBS J; 2016 Oct; 283(20):3821-3838. PubMed ID: 27588831
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
20. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
